eCite Digital Repository

Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis


Zochling, JM and Braun, J, Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis, Expert opinion on pharmacotherapy, 7, (7) pp. 869-883. ISSN 1465-6566 (2006) [Refereed Article]

DOI: doi:10.1517/14656566.7.7.869


The introduction of anti-TNFα therapy into the field of rheumatology has led to dramatic improvements in patient care, perhaps the most remarkable being in the management of ankylosing spondylitis. As experience with these compounds grows, their place in therapeutic strategy is becoming clearer, and it has been possible to develop evidence- and expertise-based recommendations for the management of ankylosing spondylitis to aid the clinician in patient care. This review outlines treatment advances in ankylosing spondylitis, including the use of anti-TNFα agents, and how these have been incorporated into clinical recommendations for daily use. © 2006 Informa UK Ltd.

Item Details

Item Type:Refereed Article
Research Division:Health Sciences
Research Group:Epidemiology
Research Field:Epidemiology not elsewhere classified
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Zochling, JM (Dr Jane Zochling)
ID Code:49163
Year Published:2006
Web of Science® Times Cited:3
Deposited By:Menzies Institute for Medical Research
Deposited On:2007-08-01
Last Modified:2012-02-17

Repository Staff Only: item control page